Myomo Q1 revenue $9.8M (+162%); record 700 pipeline adds; guides Q2 $9.0-9.5M

MYOMO, INC.

2025-Q1 EPS reported -$0.08 revenue$9,831,814

Revenue $9.8M (+162% YoY) on 182 units (+100%); gross margin 67.2% (up 600 bps).
Net loss $3.5M ($0.08/share) vs $3.8M loss last year; adj. EBITDA $(2.8)M.
Record 700 patients added to pipeline (+42% YoY); backlog 249 units (-9%).
Q2 2025 revenue guidance $9.0-9.5M; FY2025 reaffirmed at $50-53M.
Medicare Part B patients 59% of Q1 revenue; 45% of revenue from in-quarter authorizations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.